1Juntti-Berggren L, Refai E, Appelskog I, et al. Apolipoprotein C Ⅲ promotes Ca^2 + dependent β cell death in type I diabetes [ J ]. Proc Natl Acad Sci USA, 2004, 101 (27) : 10090-10094.
3Sundaram M, Zhong S, Bou Khalil M, et al. Expression of apoli- poprotein C-Ⅲ in McA-RH7777 ceils enhances VLDL assembly and secretion under lipid-rich conditions [ J]. J Lipid Res, 2010, 51 (l) : 150-161.
5Herron KL, Lofgren IE, Adiconis X, et al. Associations between plasma lipid parameters and apo C3 and apoA4 genotypes in a healthy population are independent of dietary cholesterol intake [ J]. Athero- sclerosis, 2006, 184(1): 113-120.
6Li WW, Oammerman MM, Smith JD, et al. Common genetic varia- tion in the promoter of the human apo C Ⅲ gene abolishes regulation by insulin and may contribute to hypertriglyceridemia[ J ]. J Clin In- vest, 1995, 96(6) : 2601-2605.
7Ruiz-Narvaez EA, Sacks FM, Campos H. Abdominal obesity and hy- perglycemia mask the effect of a common apo C3 haplotype on the risk of myocardial infarction[ J ]. Am J Clin Nutr, 2008, 87 (6) : 1932- 1938.
8Yu J, Wang H, Yang S, et al. The effect of apo C3 promoter poly morphisms on the risk of hypertriglyceridemia in Chinese Han popula- tion with or without type 2 diabetes mellitus[J]. Lab Med, 2010,41 (1): 34-39.
9Petersen KF, Dutour S, Hariri A, et al. Apolipoprotein C3 gene vari- ants in nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 362 (12) : 1082-1089.
10Pollin TI, Damcott CM, Shen H, et al. A null mutation in human apo C3 confers a favorable plasma lipid profile and apparent cardio- protection [ J ]. Seience, 2008, 322 ( 5908 ) : 1702-1705.
